| Status | 已發表Published |
| Artemether improves diabetic peripheral neuropathy through activation of AMPK | |
Silva, M.; Zheng, W. 
| |
| 2021-07-01 | |
| Source Publication | 7th macau symposium on Biomedical Science
 |
| Abstract | Diabetic peripheral neuropathy (DPN) affects nearly half of diabetic patients and is the commonest form of neuropathy. Characterized by spontaneous pain, paraesthesia, hyperalgesia, allodynia, or even sensory loss that may further lead to foot ulceration and amputation, gait disturbance, and fall-related injuries; it is a cause of great disability and health care burden having a significant impact in the quality of patient’s life. The mechanisms underlying DPN development are still unclear and available therapies are not effective. Therefore, the search for new effective therapies is paramount. Artemether, a derivative of artemisinin, has been used as a frontline treatment against malaria for decades. Over the years, additional therapeutic effects aside the antimalarial have been described, including anti-cancer, anti-inflammatory, anti-viral, anti-parasitic and neuroprotective. The present study aimed to assess the protective effect of artemether against DPN using an experimental animal model of diabetes induced by streptozotocin (STZ) injection. After confirmation of the development of neuropathy 4 weeks post-diabetes induction, the animals were randomly distributed into 4 groups: Group 1; control animals received daily intraperitoneal (i.p.) injections of saline; Group 2, diabetic rats received daily i.p. of saline; Group 3 and 4, diabetic rats received daily i.p. of artemether (5 or 10mg/kg) for 6 weeks. Obtained results showed that artemether significantly ameliorated STZ-diabetic animals pain responses denoted by an increase of the paw withdrawal threshold. In addition, the morphological analysis showed that diabetic rats presented severe histological abnormalities in the sciatic nerves, including degenerated nerve fibers that were reversed by artemether treatment. Further assessment of the underlying mechanisms of artemether action showed that diabetic rats exhibited a significative reduction of p-AMPK in the sciatic nerves that was inhibited by artemether. Taken together, these results suggest that artemether has a neuroprotective action against DPN and may have potential application in the prevention and treatment of DPN. |
| Keyword | Diabetic peripheral neuropathy Artemether AMPK |
| Language | 英語English |
| The Source to Article | PB_Publication |
| PUB ID | 57985 |
| Document Type | Conference paper |
| Collection | DEPARTMENT OF PHARMACEUTICAL SCIENCES |
| Corresponding Author | Zheng, W. |
| Recommended Citation GB/T 7714 | Silva, M.,Zheng, W.. Artemether improves diabetic peripheral neuropathy through activation of AMPK[C], 2021. |
| APA | Silva, M.., & Zheng, W. (2021). Artemether improves diabetic peripheral neuropathy through activation of AMPK. 7th macau symposium on Biomedical Science. |
| Files in This Item: | There are no files associated with this item. | |||||
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment